Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.62 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.62 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.62 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.62 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.62 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.62 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.62 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.62 |
| ▸ | APP | P05067 | 1/20 | 0.59 |
| ▸ | MPO | P05164 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | RORC | P51449 | 1/20 | 0.57 |
| ▸ | TUBB1 | Q9H4B7 | 6/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
| ▸ | NQO1 | P15559 | 1/20 | 0.56 |
| ▸ | NQO2 | P16083 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2565545 | 1.00 | CYP1A2 (0.77) | CYP1A2MAPTALDH1A1AOX1GRIN2D | |
| SCHEMBL13269205 | 1.00 | CYP1A2 (0.77) | CYP1A2MAPTALDH1A1AOX1GRIN2D | |
| SCHEMBL11744328 | 0.87 | MAPT (1.00) | CYP1A2MAPTALDH1A1AOX1GRIN2D | |
| SCHEMBL5075035 | 0.85 | ALDH1A1 (0.62) | CYP1A2MAPTALDH1A1APPMPO | |
| SCHEMBL7990948 | 0.85 | ALDH1A1 (0.62) | CYP1A2MAPTALDH1A1APPMPO | |
| SCHEMBL2568930 | 0.85 | ALDH1A1 (0.62) | CYP1A2MAPTALDH1A1APPMPO | |
| SCHEMBL2165442 | 0.85 | ALDH1A1 (0.65) | CYP1A2MAPTALDH1A1KDM4EGAA | |
| SCHEMBL4345928 | 0.85 | ALDH1A1 (0.65) | CYP1A2MAPTALDH1A1KDM4EGAA | |
| SCHEMBL2165438 | 0.85 | ALDH1A1 (0.65) | CYP1A2MAPTALDH1A1KDM4EGAA | |
| SCHEMBL12756980 | 0.84 | CYP1A2 (0.74) | CYP1A2MAPTALDH1A1AOX1GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6395260-B1 | SKIN LIGHTENING COMPOSITIONS | HAARMANN & REIMER GMBH (DE) | 2002-05-28 | — | — | US | claimed |
| EP-1066821-A1 | Topical cosmetic product containing benzaldoxims | HAARMANN & REIMER GMBH (DE) | 2001-01-10 | — | — | EP | claimed |
| US-9326930-B2 | Calcium sequestration compositions and methods of treating skin pigmentation disorders and conditions | NEOCUTIS S.A. (CH) | 2016-05-03 | — | — | US | disclosed |
| US-20160030321-A1 | CALCIUM SEQUESTRATION COMPOSITIONS AND METHODS OF TREATING SKIN PIGMENTATION DISORDERS AND CONDITIONS | NEOCUITIS S A (CH) | 2016-02-04 | — | — | US | disclosed |
| EP-2381918-A2 | CALCIUM SEQUESTRATION COMPOSITIONS AND METHODS OF TREATING SKIN PIGMENTATION DISORDERS AND CONDITIONS | Neocutis SA (CH) | 2011-11-02 | — | — | EP | disclosed |
| US-20100189795-A1 | CALCIUM SEQUESTRATION COMPOSITIONS AND METHODS OF TREATING SKIN PIGMENTATION DISORDERS AND CONDITIONS | NEOCUTIS S.A. (CH) | 2010-07-29 | — | — | US | disclosed |
| WO-2010083368-A2 | CALCIUM SEQUESTRATION COMPOSITIONS AND METHODS OF TREATING SKIN PIGMENTATION DISORDERS AND CONDITIONS | NEOCUTIS SA (CH) | 2010-07-22 | — | — | WO | disclosed |
| US-6395260-B1 | SKIN LIGHTENING COMPOSITIONS | HAARMANN & REIMER GMBH (DE) | 2002-05-28 | — | — | US | disclosed |
| EP-1066821-A1 | Topical cosmetic product containing benzaldoxims | HAARMANN & REIMER GMBH (DE) | 2001-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100189795-A1 | CALCIUM SEQUESTRATION COMPOSITIONS AND METHODS OF TREATING SKIN PIGMENTATION DISORDERS AND CONDITIONS | S100A4, TYR, CACYBP | CYP1A2 4277/4885MAPT 921/4885ALDH1A1 2945/4885 |
| US-20160030321-A1 | CALCIUM SEQUESTRATION COMPOSITIONS AND METHODS OF TREATING SKIN PIGMENTATION DISORDERS AND CONDITIONS | S100A4, TYR, CACYBP | CYP1A2 4277/4885MAPT 921/4885ALDH1A1 2945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.